



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 1/9

Available at: All facilities

Admit/Transfer/Discharge

Physician Note: This order set is intended for patients imminently dying of COVID 19 and not able to take oral meds

Admit

Patient Status

Resuscitation Status

Do Not Resuscitate

Diet

Diet as Tolerated

Activity

Activity as Tolerated Bedrest Reposition Patient q2h, unless static air mattress in use

Vital Signs

Vital Signs PRN Only Pain Assessment Adult q2h timed, and PRN

Notify Physician if verbal or nonverbal signs of distress are noted, and not relieved by medications or other comfort methods.

Patient Care

Oral Suction: AVOID deep suctioning

Mouth Care q2h

Edmonton Assessment Scale (ESAS) daily

Urinary Catheter Management

Urinary Catheter Intermittent Insert PRN

Urinary Catheter if Foley (14F to 18F) if distended or unable to void

Comments: Use Lidocaine 2% Jelly prior to insertion PRN

lidocaine 2% jelly (tube) 1 application Topical Gel Unscheduled PRN for Symptom Control Comments: May use prior to urinary catheter insertion

Urinary Catheter Indwelling Foley Irrigate PRN Order

Respiratory

Physician Note: Avoid (if possible) the use of fans, oxygen greater than 6 L/min, any high flow oxygen, BiPAP or CPAP, any nebulizing treatment. If these AGMP procedures are unavoidable, use appropriate isolation procedures and PPE.

Oxygen Therapy 2 – 4 L/min via Nasal Cannula PRN

Comments: If dyspnea not relieved by Oxygen, use breakthrough opioid.

SIGNATURE

NAME (PRINT)

DATE

TIME

Sent to Pharmacy (Time) _____ Copy to: _____



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 2/9

Consults

- Consult Physician: Medical Service: Palliative Care
Consult Social Work:
Aware of Consult?
Other:
End of life
Consult Spiritual-Pastoral Care: Palliative Care
Inpatient Referral to Integrated Palliative Care Program

Continuous Infusions

- Freetext Order to Nurse: No continuous intravenous infusions. Discussion with family/proxy prior to removal. May use existing IV lines for medications for symptom management but AVOID IV fluids.
Freetext Order to Nurse (Pharmacy): May insert subcutaneous butterfly for medications

Medications

Pain Management

Physician Note: If opioid naïve fentaNYL transdermal patch should NOT be initiated

- fentaNYL 12 mcg Transdermal Patch q72h timed
fentaNYL 25 mcg Transdermal Patch q72h timed
fentaNYL 37 mcg Transdermal Patch q72h timed
fentaNYL 50 mcg Transdermal Patch q72h timed
fentaNYL 62 mcg Transdermal Patch q72h timed
fentaNYL 75 mcg Transdermal Patch q72h timed
fentaNYL 87 mcg Transdermal Patch q72h timed
fentaNYL 100 mcg Transdermal Patch q72h timed

Physician Note: If opioid naïve start HYDROmorphone (Dilaudid) at 0.5 – 1 mg

Subcutaneous HYDROmorphone (Dilaudid) doses are approximately half of the oral dose

- HYDROmorphone (Dilaudid) 0.5 mg Subcutaneous Injection q4h timed
HYDROmorphone (Dilaudid) 1 mg Subcutaneous Injection q4h timed
HYDROmorphone (Dilaudid) 2 mg Subcutaneous Injection q4h timed

Physician Note: If opioid naïve start morphine at 2.5 – 5 mg

Subcutaneous morphine doses are approximately half of the oral dose

- morphine 2.5 mg Subcutaneous Injection q4h timed
morphine 5 mg Subcutaneous Injection q4h timed
morphine 10 mg Subcutaneous Injection q4h timed

SIGNATURE

NAME (PRINT)

DATE

TIME

Sent to Pharmacy (Time) Copy to:



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 3/9

Medications Continued...

Pain Management Continued...

Physician Note: If opioid naïve methadone should NOT be initiated. This is for continuation of therapy.

- methadone _____ mg rectal liquid q 8h timed
 methadone _____ mg rectal liquid q12h timed

Breakthrough Pain Management (10% of daily dose)

Physician Note: If opioid naïve start HYDROmorphone (Dilaudid) oral at 0.5 – 1 mg

Subcutaneous HYDROmorphone (Dilaudid) injection doses are approximately half of the oral dose

- HYDROmorphone (Dilaudid) _____ mg Subcutaneous Injection q1h interval PRN for Breakthrough Pain
Comments: May also use for dyspnea not relieved by oxygen

Physician Note: If opioid naïve start morphine at 2.5 – 5 mg

Subcutaneous morphine doses are approximately half of the oral dose

- morphine _____ mg subcutaneous Injection q1h interval PRN for Breakthrough Pain
Comments: May also use for dyspnea not relieved by oxygen

Medications for Additional Symptom Control:

Dyspnea

FIRST LINE:

Physician Note: If opioid naïve, start with lowest dose option

- morphine 1 mg IV q30 minutes PRN
 morphine 2.5mg IV q30 minutes PRN
 morphine 1 mg subcutaneous q30 minutes PRN
 morphine 2.5 mg subcutaneous q30 minutes PRN
 HYDROmorphone (Dilaudid) 0.25 mg IV q30 minutes PRN
 HYDROmorphone (Dilaudid) 0.5 mg IV q30 minutes PRN
 HYDROmorphone (Dilaudid) 0.25 mg subcutaneous q30 minutes PRN
 HYDROmorphone (Dilaudid) 0.5 mg subcutaneous q30 minutes PRN
 fentaNYL 12.5 mg IV q15 minutes PRN
 fentaNYL 25 mg IV q15 minutes PRN
 fentaNYL 37.5 mg IV q15 minutes PRN
 fentaNYL 50 mg IV q 15 minutes PRN
 fentaNYL 12.5 mg subcutaneous q15 minutes PRN
 fentaNYL 25 mg subcutaneous q15 minutes PRN
 fentaNYL 37.5 mg IV q15 minutes PRN
 fentaNYL 50 mg subcutaneous q15 minutes PRN

SIGNATURE NAME (PRINT) DATE TIME

Sent to Pharmacy (Time) _____ Copy to: _____



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 4/9

Medications Continued...

Medications for Additional Symptom Control Continued...

Dyspnea

FIRST LINE CONTINUED...

If opioid tolerant

- checkbox morphine _____ mg subcutaneous q30 minutes PRN
Comment: For dyspnea, use 10% of the total daily dose of Subcutaneous or IV opioid in 24 hours
checkbox morphine _____ mg IV q30 minutes PRN
Comment: For dyspnea, use 10% of the total daily dose of Subcutaneous or IV opioid in 24 hours
checkbox HYDROMORPHONE _____ mg subcutaneous q 30 minutes PRN
Comment: For dyspnea, use 10% of the total daily dose of Subcutaneous or IV opioid in 24 hours
checkbox HYDROMORPHONE _____ mg IV q 30 minutes PRN
Comment: For dyspnea, use 10% of the total daily dose of Subcutaneous or IV opioid in 24 hours

SECOND LINE:

- checkbox midazolam 0.5 mg IV q30 minutes PRN
checkbox midazolam 0.5 mg subcutaneous q30 minutes PRN
checkbox midazolam 1 mg IV q30 minutes PRN
checkbox midazolam 1 mg subcutaneous q30 minutes PRN
checkbox midazolam 2.5 mg subcutaneous q15 minutes PRN

Physician Note: If severe respiratory distress consider ketamine in dissociative dosing as a temporary measure

- checkbox ketamine _____ mg (1-2 mg/kg) IV ONCE PRN
Comment: If available at facility
checkbox ketamine _____ (4mg/kg) IM ONCE PRN
Comment: If available at facility

Agitation/Delirium/Restlessness

- checkbox haloperidol 1 mg Subcutaneous Injection q2h timed PRN for Agitation/delirium
checkbox haloperidol 2 mg Subcutaneous Injection q2h timed PRN for Agitation/delirium
checkbox haloperidol 2.5 mg Subcutaneous Injection q2h timed PRN for SEVERE agitation
checkbox haloperidol 5 mg Subcutaneous Injection q2h timed PRN for SEVERE agitation
checkbox methotrimeprazine 12.5 mg Subcutaneous Injection q4h timed PRN for Agitation/delirium
Comments: **Notify MD if patients require more than 4 doses in a 24 hour period as methotrimeprazine is also used for palliative sedation**
checkbox methotrimeprazine 25 mg Subcutaneous Injection q4h timed PRN for Agitation/delirium
Comments: **Notify MD if patients require more than 4 doses in a 24 hour period as methotrimeprazine is also used for palliative sedation**
checkbox midazolam 2.5 mg subcutaneous q 2h PRN for Agitation/Delirium
checkbox midazolam 5 mg subcutaneous q 2h PRN for Agitation/Delirium

SIGNATURE

NAME (PRINT)

DATE

TIME

checkbox Sent to Pharmacy (Time) _____ checkbox Copy to: _____



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 5/9

Medications Continued...

Medications For Additional Symptom Control Continued...

Pulmonary Congestion Management

- glycopyrrolate 0.2 mg Subcutaneous Injection q2h timed PRN for symptom control, For management of pulmonary congestion
glycopyrrolate 0.4 mg Subcutaneous Injection q2h timed PRN for symptom control, For management of pulmonary congestion
scopolamine 0.4 mg Subcutaneous Injection q2h timed PRN for symptom control, For management of pulmonary congestion
scopolamine 0.6 mg Subcutaneous Injection q2h timed PRN for symptom control, For management of pulmonary congestion
furosemide 20 mg IV q2h timed PRN for symptom control, For management of pulmonary congestion
furosemide 20 mg subcutaneous q2h timed PRN for symptom control, For management of pulmonary congestion
furosemide 40 mg IV q2h timed PRN for symptom control, For management of pulmonary congestion
furosemide 40 mg subcutaneous q2h timed PRN for symptom control, For management of pulmonary congestion

Crisis Respiratory Failure

Physician Note: Crisis Respiratory Failure is defined as: Patient rating Shortness of Breath 10/10, patient imminently dying, rapid and severe worsening of respiratory status (O2 sat. drop) over short hours along overall decline. Please see associated document entitled Crisis Respiratory Failure Flowchart

- midazolam 5 mg subcutaneous Unscheduled PRN
Comments: STAT and q 10 minutes PRN. Step 2 of Crisis Respiratory Failure – See associated document
midazolam 5 mg IV Unscheduled PRN
Comments: STAT and q 10 minutes PRN. Step 2 of Crisis Respiratory Failure – See associated document
methotrimeprazine 25 mg subcutaneous Unscheduled PRN
Comments: STAT and q 30 minutes PRN. Step 3 of Crisis Respiratory Failure– See associated document
methotrimeprazine 25 mg IV Unscheduled PRN
Comments: STAT and q 30 minutes PRN. Step 3 of Crisis Respiratory Failure– See associated document
methotrimeprazine 50 mg subcutaneous Unscheduled PRN
Comments: STAT and q 30 minutes PRN. Step 3 of Crisis Respiratory Failure– See associated document
methotrimeprazine 50 mg IV Unscheduled PRN
Comments: STAT and q 30 minutes PRN. Step 3 of Crisis Respiratory Failure– See associated document

SIGNATURE

NAME (PRINT)

DATE

TIME

Sent to Pharmacy (Time) _____ Copy to: _____



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 6/9

Medications Continued...

Medications For Additional Symptom Control Continued...

Second Line Medications for Palliative Sedation (in the event the medications for Crisis Respiratory Failure are unavailable)

LORAZEPAM

Physician Note: LORazepam IV infusion

- LORazepam 0.5 mg/hr IV infusion
Comments: Max: 0.1 mg/kg/h or 4 mg/hr
- LORazepam 1 mg/hr IV infusion
Comments: Max: 0.1 mg/kg/h or 4 mg/hr

Physician Note: LORazepam IV push

- LORazepam 1 mg q4h IV PRN Sedation
Comments: Max: 8 mg q2h PRN
- LORazepam 2 mg q4h IV PRN Sedation
Comments: Max: 8 mg q2h PRN
- LORazepam 4 mg q4h IV PRN Sedation
Comments: Max: 8 mg q2h PRN
- LORazepam 8 mg q4h IV PRN Sedation
Comments: Max: 8 mg q2h PRN

Physician Note: LORazepam Buccal

- LORazepam 1 mg q4h buccal PRN Sedation
Comments: Max: 8 mg q2h PRN
- LORazepam 2 mg q4h buccal PRN Sedation
Comments: Max: 8 mg q2h PRN
- LORazepam 4 mg q4h buccal PRN Sedation
Comments: Max: 8 mg q2h PRN
- LORazepam 8 mg q4h buccal PRN Sedation
Comments: Max: 8 mg q2h PRN

SIGNATURE NAME (PRINT) DATE TIME

Sent to Pharmacy (Time) _____ Copy to: _____



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 7/9

Medications Continued...

Medications For Additional Symptom Control Continued...

PHENOBARBITAL

- PHENobarbital 15 mg subcutaneous q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 30 mg subcutaneous q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 60 mg subcutaneous q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 15 mg IV q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 30 mg IV q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 60 mg IV q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 15 mg PR q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 30 mg PR q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses
PHENobarbital 60 mg PR q4h PRN Sedation
Comments: up to 1,600 mg/day in divided doses

OLANZAPINE ODT

- OLANZapine ODT 2.5 mg PO daily PRN Sedation
Comments: May give in one to two divided doses to treat severe delirium
OLANZapine ODT 5 mg PO daily PRN Sedation
Comments: may give in one to two divided doses to treat severe delirium
OLANZapine ODT 10 mg PO daily PRN Sedation
Comments: may give in one to two divided doses to treat severe delirium
OLANZapine ODT 20 mg PO daily PRN Sedation
Comments: may give in one to two divided doses to treat severe delirium

SIGNATURE

NAME (PRINT)

DATE

TIME

Sent to Pharmacy (Time) Copy to:



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Page 8/9

Medications Continued...

Medications For Additional Symptom Control Continued...

Bowel Management

- DO NOT Initiate Bowel Care Protocol
PROTOCOL Bowel Care Clinical Opioid
bisacodyl 10 mg Rectal Suppository q3days PRN for Constipation
monobasic sodium phosphate monohydrate - dibasic sodium phosphate (Fleet Enema) 19 g - 7 g 130 mL Rectal Enema Once PRN for Constipation "High Fleet"
High Oil Retention Enema 1 each Rectal Enema Unscheduled PRN for Constipation

Fever Management

- acetaminophen 325 - 650 mg Rectal Suppository q4h timed PRN for Fever
Comments: Max from all sources 4,000 mg in 24 hours if T greater than/equal to 38.5°C

Eye/Oral Care Management

- hydroxypropyl methylcellulose 0.5% ophthalmic 2 drop(s) Eyes each Drop q2h timed PRN for Dry eyes
Moistir 1 spray(s) Oral Spray Unscheduled PRN for Dry mouth
Oral Balance 1 application Oral Gel Unscheduled PRN for Dry mouth

Nausea Management

- haloperidol 0.5 mg Subcutaneous Injection q4h timed PRN for Nausea
haloperidol 1 mg Subcutaneous Injection q4h timed PRN for Nausea
ondansetron 4 mg Subcutaneous Injection/IV q6h timed PRN
ondansetron 8 mg Subcutaneous Injection/IV q6h timed PRN

Upon Death

- May release body to morgue upon death
No autopsy required
Autopsy; contact most responsible provider upon death

SIGNATURE NAME (PRINT) DATE TIME

Sent to Pharmacy (Time) Copy to:



PATIENT LABEL

Patient Name: _____

PHN: _____

COVID-19 PAL Last Days of Living Order Set

Additional Orders

Multiple horizontal lines for entering additional orders.

SIGNATURE NAME (PRINT) DATE TIME

Sent to Pharmacy (Time) _____ Copy to: _____